Epclusa
sofosbuvir / velpatasvir
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Epclusa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Epclusa.
For practical information about using Epclusa, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Epclusa : EPAR - Summary for the public (PDF/81.57 KB)
First published: 28/07/2016
Last updated: 28/07/2016 -
-
List item
Epclusa : EPAR - Risk-management-plan summary (PDF/59.31 KB)
First published: 21/02/2019
Last updated: 06/11/2019
Authorisation details
Product details | |
---|---|
Name |
Epclusa
|
Agency product number |
EMEA/H/C/004210
|
Active substance |
|
International non-proprietary name (INN) or common name |
sofosbuvir / velpatasvir
|
Therapeutic area (MeSH) |
Hepatitis C, Chronic
|
Anatomical therapeutic chemical (ATC) code |
J05A
|
Accelerated assessment |
This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment. |
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
Gilead Sciences Ireland UC
|
Revision |
10
|
Date of issue of marketing authorisation valid throughout the European Union |
06/07/2016
|
Contact address |
Product information
21/10/2019 Epclusa - EMEA/H/C/004210 - WS/1518
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Antivirals for systemic use
Therapeutic indication
Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults.